English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Horizon Therapeutics
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily
| May 7, 2023
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily
| May 7, 2023
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily
| Apr 24, 2023
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Patient Daily
| Apr 24, 2023
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Patient Daily
| Apr 24, 2023
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Trending
Patient Daily
| Oct 22, 2025
Chronic Care Policy Alliance backs federal legislation to reform the 340B Drug Pricing Program
Patient Daily
| Oct 23, 2025
Dallas Breathe Free ENT Specialist: Humidity 'tends to help' with sinus issues
Patient Daily
| Oct 23, 2025
Capitol Breathe Free Otolaryngologist: ‘Allergy exacerbations are a common trigger for sinus infections'
Patient Daily
| Oct 21, 2025
Gulf Coast Breathe Free Physician Assistant on sinus issues: ‘Certain things like dairy seem to increase mucus production’